30 closest matches · ranked by relevance
Extrahepatic Bile Duct Cancer · Gallbladder Cancer
Primary: Stratum-specific (R0 and R1) 2-year Overall Survival — 67; 60 percentage of participants
Cholangiocarcinoma
Primary: Number of Patients Experiencing a Clinically Relevant Complications — 1; 7 Participants
Adult Primary Cholangiocellular Carcinoma · Advanced Adult Primary Liver Cancer · Cholangiocarcinoma of the Extrahepatic Bile Duct
Primary: Overall Survival — 4.7; 1.6; 3.94 months
Cancer of the Gallbladder · Cancer of the Biliary Tract
Primary: Number of Participants With Objective Response — 1 participants
Cholangiocarcinoma
Primary: Progression-Free Survival (PFS) Rate at 6 Months (Proportion of Participants Alive and Progression-Free at 6 Months) — 0.605 proportion of participants
Extrahepatic Bile Duct Adenocarcinoma · Gallbladder Adenocarcinoma · Gallbladder Adenocarcinoma With Squamous Metaplasia
Primary: Progression-free Survival — 2 months
Cholangiocarcinoma
Primary: Objective Response Rate (ORR) — 0; 0 Participants
Metastatic Biliary Tract Carcinoma
Primary: Progression-free Survival (PFS) — 3.58 months
Biliary Carcinoma · Gall Bladder Carcinoma · Cholangiocarcinoma
Primary: Progression Free Survival (PFS) — 6.2 months
Cholangiocarcinoma
Primary: Number of Subjects Where Hilar Cholangiocarcinomas Could be Visualized Using Gadoxetate Disodium Enhanced Dual Energy CT — 5 participants
Extrahepatic Bile Duct Cancer · Gallbladder Cancer
Primary: Response — 7; 6; 12; 15 participants
Bile Duct Cancer · Intrahepatic Cholangiocarcinoma · Cholangiocarcinoma of the Extrahepatic Bile Duct
Primary: Median Progression Free Survival (PFS) — 1.8 months
Cholangiocarcinoma
Primary: Objective Response Rate (ORR) in Participants With FGFR2 Rearrangements or Fusions — 37.0 percentage of participants
Cholangiocarcinoma
Primary: Objective Response Rate (ORR) — 2 Participants
Intrahepatic Cholangiocarcinoma · Combined Hepatocellular and Cholangiocarcinoma
Primary: Substudy 1: Objective Response Rate (ORR) — 22.3 Percentage of participants
Adenocarcinoma
Primary: Progression-free Survival (PFS) — 91; 148 days
Advanced Cholangiocarcinoma · Metastatic Cholangiocarcinoma
Primary: Progression Free Survival (PFS) as Determined by the Independent Radiology Committee (IRC) — 2.7; 1.4 months — p=<0.0001
Extrahepatic Bile Duct Cancer · Gallbladder Cancer
Primary: Progression-Free Survival — 51 percentage of participants
Resectable Cholangiocarcinoma · Stage IB Intrahepatic Cholangiocarcinoma AJCC v8 · Stage II Intrahepatic Cholangiocarcinoma AJCC v8
Primary: Number of Participants Who Completed All Preoperative and Operative Therapy — 22 Participants
Metastatic Cholangiocarcinoma · Cholangiocarcinoma · Pancreatic Cancer
Primary: Objective Response Rate (ORR) Using Response Evaluation Criteria for Solid Tumors (RECIST 1.1) — 0; 3 Participants
Cholangiocarcinoma Cancer · Gallbladder Cancer · Pancreatic Cancer
Primary: Incidence of Severe Toxicities — 20 percentage of participants
Advanced Biliary Tract Carcinoma
Primary: MTD of MEK162 - Phase I — 45 mg
Hilar Cholangiocarcinoma
Primary: Proportion of Patients With Adequate Biliary Drainage in Metallic Stent and Plastic Stent Group.(ITT Analysis) — .7037037; .46296 proportion of participants — p=0.011
Cholangiocarcinoma
Primary: Median Progression Free Survival (PFS) — 6 months
Biliary Tract Cancer · Cholangiocarcinoma · Gallbladder Cancer
Primary: Percentage of Participants With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by…
Biliary Cancer · Cholangiocarcinoma
Primary: Progression Free Survival Rate at Five Months — 69 percentage of participants
Biliary Tract Cancer · Gallbladder Cancer
Primary: The Number of Participants With Response to GEMOX-Panitumumab (GEMOX-P) in Chemotherapy naïve KRAS/ BRAF Wild Type Stage IV Biliary Tract Cancer Using the Response…
Unresectable Intrahepatic Cholangiocarcinoma
Primary: Tumor Response (Overall Response = Complete Response + Partial Response + Progressive Disease + Stable Disease) — 24; 22 participants
Unresectable Intrahepatic Cholangiocarcinoma
Primary: Objective Response Rate (ORR) Per mRECIST (Modified RECIST) — 1 Participants
Cholangiocarcinoma
Primary: The Primary Objective of This Study is to Assess Progression Free Survival (PFS) With Proposed Therapy for Patients With Locally Advanced or Metastatic Gallbladder and…